ArticleThe World Allergy Organization journal2025
Effectiveness of transitioning from omalizumab to dupilumab in chronic spontaneous urticaria patients with inadequate response to omalizumab.
Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Targeted Therapy for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Critical Narrative Review and an Evidence-Graded Approach to Agent Selection.Antibodies (Basel, Switzerland) · 2026Review
- Successful Treatment of Refractory Chronic Spontaneous Urticaria with Stapokibart After Omalizumab Failure: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- Omalizumab to dupilumab switch in chronic spontaneous urticaria.The World Allergy Organization journal · 2025Article
- Response to comments on "Effectiveness of transitioning from omalizumab to dupilumab in chronic spontaneous urticaria patients with inadequate response to omalizumab".The World Allergy Organization journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dupilumab is effective for chronic spontaneous urticaria (CSU), but its clinical benefit of switching to dupilumab in omalizumab-resistant CSU remains unclear. This prospective pilot study evaluated the effectiveness of dupilumab in 12 CSU patients whose Urticaria Control Test (UCT) scores remained <12 after receiving at least 4 doses of omalizumab. Patients were transitioned to dupilumab after inadequate response to omalizumab. UCT scores were assessed at baseline, and 1 and 4 months after starting dupilumab. Laboratory parameters including eosinophil and basophil counts, total IgE, C-reactive protein, and anti-thyroid peroxidase antibody levels were also evaluated. The mean UCT score at the initiation of dupilumab was 6.5 ± 2.2, improving to 8.4 ± 3.0 at 1 month (P = 0.016) and 8.1 ± 3.9 at 4 months (P = 0.045), compared to 4.9 ± 3.1 before omalizumab treatment. Three patients achieved UCT ≥12 after switching to dupilumab. No significant differences were found in clinical characteristics or laboratory markers between effective and ineffective groups. Interestingly, 3 patients who returned to omalizumab after inadequate response to dupilumab achieved UCT ≥12. Dupilumab may improve disease control in a subset of omalizumab-resistant CSU patients. Further studies are needed to identify which patients benefit most from switching therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.